Clinical Focus Target neuropsychiatric indications with high unmet need, including PTSD, Social Anxiety Disorder, Opioid Addiction, Smoking Cessation, and childhood epilepsy, leveraging Nantheia and Liquid Structure delivery to differentiate on bioavailability and delivery stability.

Strategic Partnerships Leverage prior academia and hospital collaborations (University of Nebraska Medical Center, UCLA) and NIH-backed trials to open co-development and funding opportunities, while presenting as a validated, evidence-driven partner for CNS program collaborations.

Regulatory & IP Highlight FDA IND approvals and patent protection across 35+ markets through 2040+ to de-risk investments, enabling BD conversations around international licensing, regional partnerships, and early-access programs.

Manufacturing Advantage Promote GxP-compliant, scalable manufacturing infrastructure with proprietary Liquid Structure delivery to support supply commitments, phase-appropriate manufacturing scale, and potential contract manufacturing opportunities for CBD-related therapeutics.

Financial & Growth Signals Appeal to investors and potential customers by noting credible revenue range and targeted clinical milestones, while aligning sales goals to upcoming PTSD trials and expansion of the CNS pipeline to broaden market opportunities.